Literature DB >> 11583185

ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV).

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11583185     DOI： 10.1023/a:1017413507554

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

1.  Nausea and emesis: still an unsolved problem in cancer patients?

Authors:  Jørn Herrstedt
Journal:  Support Care Cancer       Date:  2002-01-31       Impact factor: 3.603

2.  The importance of clinical practice guidelines (CPGs) for the quality and development of supportive care in Central and Eastern European (CEE) countries.

Authors:  Snezana Bosnjak
Journal:  Support Care Cancer       Date:  2003-10-15       Impact factor: 3.603

3.  The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms.

Authors:  Giuseppe Riezzo; Caterina Clemente; Silvana Leo; Francesco Russo
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

Review 4.  Acute emesis: moderately emetogenic chemotherapy.

Authors:  Jørn Herrstedt; Jim M Koeller; Fausto Roila; Paul J Hesketh; David Warr; Cynthia Rittenberg; Mario Dicato
Journal:  Support Care Cancer       Date:  2004-11-23       Impact factor: 3.603

5.  Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy.

Authors: 
Journal:  Support Care Cancer       Date:  2003-10-25       Impact factor: 3.603

Review 6.  Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.

Authors:  Toni M Dando; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Delayed emesis: moderately emetogenic chemotherapy.

Authors:  Fausto Roila; David Warr; Rebecca A Clark-Snow; Maurizio Tonato; Richard J Gralla; Lawrence H Einhorn; Jorn Herrstedt
Journal:  Support Care Cancer       Date:  2004-11-12       Impact factor: 3.603

8.  Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.

Authors:  J Vardy; K S Chiew; J Galica; G R Pond; I F Tannock
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.